Breast Cancer

The Pharmacy Times® Breast Cancer resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.

What can we help you find?
[[thumbnail_alt_text]]
According to study findings published in Cancer, mammography screenings reduce the rates of advanced and fatal cancers by more than 40%.
[[thumbnail_alt_text]]
The anti-cancer medicine venetoclax may improve the current therapy for estrogen receptor-positive (ER+) breast cancer.
[[thumbnail_alt_text]]
Although the average wholesale price of the agents is more than $13,000, the investigators found that 9% of patients had a 0% co-pay throughout the 6-month period.
 
[[thumbnail_alt_text]]
A community pharmacy-based intervention program was utilized to enhance AET adherence.
[[thumbnail_alt_text]]
Sacituzumab govitecan-hziy, approved by the FDA on April 22, 2020, is the first in its class to treat metastatic, triple-negative breast cancer in patients who have received at least 2 prior therapies for metastatic disease.
[[thumbnail_alt_text]]
In outpatient breast cancer clinics, oral chemotherapies are becoming more common for various malignancies, but hematologic and non-hematologic toxicities can cause challenges for patients.
[[thumbnail_alt_text]]
According to the investigators, the cells are called ductal macrophages and function by consuming dying milk-producing cells, which need to be cleared away after milk production stops.
[[thumbnail_alt_text]]
The objective of the study was to develop an education program that increased confidence and knowledge of pharmacists managing CDK4/6 inhibitors.
[[thumbnail_alt_text]]
In the oral chemotherapy setting, pharmacist care exceeded patients’ expectations and helped manage and avoid adverse events (AEs).
 
[[thumbnail_alt_text]]
Researchers have developed a new way to map the molecules on tumor cells that flag their presence to the immune system.
[[thumbnail_alt_text]]
The findings are part of the I-SPY clinical trial and were presented at the American Association for Cancer Research virtual annual meeting.
 
[[thumbnail_alt_text]]
The objective of the study was to examine whether positive treatment effects in cancer randomized clinical trials apply to specific demographic or insurance subgroups.